Hypothesis
fatigue, toxicity, prostate, sexual dysfunction, depression
GYNECOMASTIA, PROSTATE
The hypothesis of this phase I study is that combining EBRT and ADT (in accordance to current standard of care) with one cycle of systemic [The toxicity profile of ADT has been reported extensively, and includes e.g. fatigue, sexual dysfunction, gynecomastia, flushes and depression [The acute toxicity of EBRT of the prostate and pelvic nodes with concurrent ADT has also been reported extensively, for example in the PIVOTAL study in 2018 [[Based on these patterns we hypothesize that tolerability of EBRT and ADT will not be affected by adding one administration of up to nine GBq [Based on these considerations, the risk of significant extra toxicity due to the addition of one cycle of [